NewAmsterdam Pharma Announces 2024 Strategic Priorities
-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase...
Clinical Trial
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic...
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenzaNEW YORK, Jan....
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that...
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular...
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing...
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer...
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track...
ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
– First-in-human clinical trial evaluating QTX3034 as monotherapy and combination in patients with KRASG12D-mutated advanced solid tumors to begin in...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing...
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored...
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate...
Cognition Therapeutics CEO Issues Letter to Shareholders
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from...
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in...
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product...
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
KELOWNA, BC / ACCESSWIRE / January 4, 2024 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology...
Angle PLC Announces Breakthrough Clinical Results
BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCERCombined DNA Next Generation Sequencing of CTCs...
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging...